Nektar Therapeutics (NKTR) Payables: 2010-2025
Historic Payables for Nektar Therapeutics (NKTR) over the last 15 years, with Sep 2025 value amounting to $15.6 million.
- Nektar Therapeutics' Payables rose 81.45% to $15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.2 million, marking a year-over-year increase of 76.00%. This contributed to the annual value of $11.6 million for FY2024, which is 17.38% up from last year.
- Per Nektar Therapeutics' latest filing, its Payables stood at $15.6 million for Q3 2025, which was up 8.98% from $14.3 million recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' Payables ranged from a high of $23.7 million in Q3 2021 and a low of $2.6 million during Q2 2023.
- Moreover, its 3-year median value for Payables was $8.8 million (2024), whereas its average is $9.3 million.
- In the last 5 years, Nektar Therapeutics' Payables slumped by 78.79% in 2023 and then surged by 160.86% in 2024.
- Over the past 5 years, Nektar Therapeutics' Payables (Quarterly) stood at $9.7 million in 2021, then skyrocketed by 33.17% to $13.0 million in 2022, then decreased by 24.13% to $9.8 million in 2023, then climbed by 17.38% to $11.6 million in 2024, then surged by 81.45% to $15.6 million in 2025.
- Its Payables was $15.6 million in Q3 2025, compared to $14.3 million in Q2 2025 and $17.8 million in Q1 2025.